Enterprise Value
330.5M
Cash
23.87M
Avg Qtr Burn
-1.595M
Short % of Float
3.50%
Insider Ownership
5.03%
Institutional Own.
34.33%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZUPLENZ (ondansetron) Details Nausea and vomiting | Approved Quarterly sales | |
KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details Parkinson’s disease (OFF Episodes / motor fluctuations) | Approved Quarterly sales | |
Exservan™ (riluzole) Oral Film Details Amyotrophic Lateral Sclerosis (ALS) | Approved Quarterly sales | |
SUBOXONE (buprenorphine/naloxone) Details Opioid addiction | Approved Quarterly sales | |
PDUFA Approval decision | ||
NDA Submission | ||
AQST-119 Details Erectile dysfunction
| Failed Discontinued |